Redeye returns with a more detailed take on the Q4 report following the conference call and discussions with management. We continue to have a positive view of the company’s outlook for 2021, with reinforced confidence in management’s capabilities in its quest to build this emerging compounder. Nearing catalyst in the form of an FDA approval is likely to take the share to our Base Case of SEK 90 before the end of Q1.